Blair William & CO Chinook Therapeutics, Inc. Transaction History

Blair William & CO

5 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q1 2022 May 13, 2022	SELL	$12.02 - $16.69 $128,950 - $179,050	-10,728 Closed	0 $0
Q4 2021 Feb 14, 2022	SELL	$10.69 - $16.83 $116,756 - $183,817	-10,922 Reduced 50.45%	10,728 $175,000
Q3 2021 Nov 12, 2021	BUY	$11.5 - $14.86 $125,350 - $161,974	10,900 Added 101.4%	21,650 $276,000
Q2 2021 Aug 12, 2021	SELL	$13.6 - $18.98 $95,200 - $132,860	-7,000 Reduced 39.44%	10,750 $152,000
Q1 2021 May 13, 2021	BUY	$14.17 - $19.11 $251,517 - $339,202	17,750 New	17,750 $276,000

234K

Ticker KDNY
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 62,896,300
Description
Chinook Therapeutics, Inc., a clinical-stage biotechnology company, focuses on the discovery, development, and commercialization of precision medicines for kidney diseases. The company's lead clinical program is atrasentan, a Phase III endothelin receptor antagonist for the treatment of IgA nephropathy and other proteinuric glomerular diseases. ...

Get notified when there are updates to the investment portfolio of Blair William & CO, based on Form 13F filings with the SEC.

Stay updated on Blair William & CO with notifications on news.